Cancer Chemical Biology Faculty
Derek Duckett, PhD - Senior Member
Research in the Duckett lab is focused on identifying novel anti-cancer targets , developing small molecule probes against these targets and interrogating how their altered signaling drives tumor progression, metastasis and therapy resistance.
Haitao (Mark) Ji, PhD - Associate Member
The Ji lab research focuses on the design and synthesis of small molecules that can modulate cancer-related cellular signaling pathways with an emphasis on protein-protein interactions and target specificity.
Research Themes: Rational Drug Design and Synthesis, Protein–Protein Interaction Inhibition and Regulation, Medicinal Chemistry, Signaling Pathways
John M. Koomen, PhD – Associate Member
The Koomen Lab uses mass spectrometry-based techniques to better understand cancer biology, evaluate hypotheses derived from basic science experiments in human tumors, and contribute to the development of novel strategies for patient assessment and treatment.
Nicholas James Lawrence, PhD - Associate Member
Dr. Lawrence's group efforts are focused on the synthesis of new anticancer agents. The goal of the laboratory is to design and develop synthetic methodology to provide small organic molecules to act as selective anticancer agents against a range of molecular targets.
Justin M. Lopchuk, PhD - Assistant Member
Our research program is grounded in synthetic organic chemistry with a specific focus on the development of new reactions, the design of new reagents, and the total synthesis of natural products with anti-cancer activity.
Vince C. Luca, PhD - Assistant Member
The Luca Lab studies the "molecular language" of cell-to-cell communication using cutting edge approaches in structural, cellular and synthetic biology. Our goal is to visualize how cells send and receive information at the atomic level, and to harness this insight to guide the engineering of next-generation cancer therapeutics.
Uwe Rix, PhD – Associate Member
I am interested in targeted drugs, drug-protein interaction networks and drug synergy, particularly in the context of lung cancer, melanoma and their microenvironments. I am pursuing a multi-layered chemical biology/systems pharmacology strategy by screening for unexpected drug activity and identifying the molecular mechanisms of action through e.g. combining chemical proteomics and phosphoproteomics.
Ernst Schonbrunn, PhD - Associate Member
Research from the Schönbrunn laboratory focuses on the elucidation of the structure-activity relationship of medicinally important proteins. We use protein crystallography combined with methods in biochemistry, molecular biology and medicinal chemistry to explore proteins at the atomic level. Our aim is to identify "weak sites" in those proteins that can be targeted by new inhibitors with potential as future drugs.
Said M. Sebti, PhD - Senior Member
Dr. Sebti's lab's research interests are focused on understanding the mechanisms by which aberrant signal transduction pathways contribute to oncogenesis and developing novel anticancer drugs based on interfering with these pathways.